Alliancebernstein L.P. Has $1.83 Million Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Alliancebernstein L.P. lifted its position in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 77.7% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 313,982 shares of the company's stock after buying an additional 137,319 shares during the period. Alliancebernstein L.P. owned 0.55% of Olema Pharmaceuticals worth $1,831,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. KLP Kapitalforvaltning AS acquired a new stake in shares of Olema Pharmaceuticals in the fourth quarter worth $30,000. Teacher Retirement System of Texas bought a new stake in Olema Pharmaceuticals in the fourth quarter valued at about $60,000. Vontobel Holding Ltd. bought a new stake in Olema Pharmaceuticals in the fourth quarter valued at about $62,000. Fox Run Management L.L.C. bought a new stake in Olema Pharmaceuticals in the fourth quarter valued at about $80,000. Finally, SG Americas Securities LLC increased its holdings in Olema Pharmaceuticals by 33.8% in the fourth quarter. SG Americas Securities LLC now owns 17,475 shares of the company's stock valued at $102,000 after buying an additional 4,419 shares during the last quarter. Hedge funds and other institutional investors own 91.78% of the company's stock.

Analysts Set New Price Targets

OLMA has been the subject of several research analyst reports. JPMorgan Chase & Co. lowered their price objective on Olema Pharmaceuticals from $30.00 to $28.00 and set an "overweight" rating for the company in a report on Friday, March 28th. Oppenheimer reiterated an "outperform" rating and set a $25.00 price objective (down from $30.00) on shares of Olema Pharmaceuticals in a research report on Wednesday, March 19th. Finally, HC Wainwright reissued a "buy" rating and set a $30.00 target price on shares of Olema Pharmaceuticals in a report on Wednesday, March 19th.

Olema Pharmaceuticals Stock Up 1.8 %

NASDAQ OLMA traded up $0.09 during trading on Wednesday, hitting $5.05. The company's stock had a trading volume of 116,782 shares, compared to its average volume of 857,581. The firm has a market cap of $345.08 million, a P/E ratio of -2.31 and a beta of 2.10. Olema Pharmaceuticals, Inc. has a 52 week low of $2.86 and a 52 week high of $16.62. The firm has a 50 day moving average price of $4.20 and a 200 day moving average price of $6.94.

Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last announced its earnings results on Tuesday, March 18th. The company reported ($0.51) earnings per share for the quarter, beating analysts' consensus estimates of ($0.63) by $0.12. On average, equities analysts expect that Olema Pharmaceuticals, Inc. will post -2.33 earnings per share for the current year.

Olema Pharmaceuticals Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.